baricitinib · Olumiant
Small molecule
Evidence outlook
Approved: Rheumatoid Arthritis, Alopecia Areata, COVID-19
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Atopic Dermatitis · Phase 3 · investigational in the US
Also approved (6)
- OLUMIANT (baricitinib tablets) is indicated for: Rheumatoid Arthritis (RA) • In combination with methotrexate (MTX), for reducing the signs and symptoms of moderate to severe rheumatoid arthritis (RA) in adult patients who have responded inadequately to one or more disease-modifying anti-rheumatic drugs (DMARDs). OLUMIANT may be used as monotherapy in cases of intolerance to MTX. Limitations of Use: Use of OLUMIANT in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended (see 7 WARNINGS AND...
- Rheumatoid arthritis with inadequate response to standard of care (2 mg and 4 mg tablets)
- Olumiant: moderate to severe active rheumatoid arthritis in adults; holder Eli Lilly Nederland B.V.
- Moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy (Olumiant)
- Treatment of active juvenile idiopathic arthritis in patients 2 years of age and older (Olumiant)
- Treatment of severe alopecia areata in adult and adolescent patients 12 years of age and older (Olumiant)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
RA-BEAM NCT01710358 · Rheumatoid Arthritis This was a large, randomized, quadruple-blind, placebo-controlled trial using a validated composite measure of rheumatoid arthritis response, and significantly more patients responded on baricitinib than on placebo. Registry: NCT01710358 | 3 | Percentage of Participants Achieving American College of Rheumatology 20% Improvement (ACR20) (Week 12) 2015-03 | ACR20 response at Week 12 (primary endpoint): 70% baricitinib 4mg vs 40% placebo (P<0.001) | Reliable signal | link ↗ |
View 6 more trials
RA-BEGIN NCT01711359 · Rheumatoid Arthritis This was a randomized, quadruple-blind, active-controlled trial in patients new to methotrexate, using a validated composite measure of rheumatoid arthritis response, and baricitinib monotherapy met its prespecified comparison against methotrexate, with the entire confidence interval favoring baricitinib. Registry: NCT01711359 | 3 | Percentage of Participants Achieving American College of Rheumatology 20% Improvement (ACR20) (Week 24) 2015-02 | ACR20 response at Week 24 (primary endpoint): 77% baricitinib monotherapy vs 62% methotrexate monotherapy (P≤0.01); baricitinib was noninferior and superior to methotrexate | Reliable signal | link ↗ |
NCT02265705 NCT02265705 · Rheumatoid Arthritis This was a randomized, double-blind, placebo-controlled trial using a validated composite measure of rheumatoid arthritis response, and significantly more patients responded on baricitinib than on placebo. Registry: NCT02265705 | 3 | Percentage of Participants Achieving 20% Improvement in American College of Rheumatology Criteria (ACR20) (Week 12) 2017-05 | ACR20 response at Week 12 (primary endpoint, 290 randomized, 145 per arm): 58.6% baricitinib 4mg vs 28.3% placebo (OR 4.1, 95% CI 2.5-6.9; p=0.001) | Reliable signal | link ↗ |
NCT01185353 NCT01185353 · Rheumatoid Arthritis Registry: NCT01185353 | 2 | Percentage of Participants in the 4 mg and 8 mg Dose Groups Who Achieved an American College of Rheumatology 20 (ACR20) Responder Index Response Baseline Through Week 12 2011-12 | Percentage of Participants in the 4 mg and 8 mg Dose Groups Who Achieved an American College of Rheumatology 20 (ACR20) Responder Index Response Baseline Through Week 12 (Baseline through Week 12): 4 or 8 mg LY3009104 76 percentage of participants | Placebo 41 percentage of participants | not yet graded | link ↗ |
NCT01469013 NCT01469013 · Rheumatoid Arthritis Registry: NCT01469013 | 2 | Percentage of Participants in the 4 mg and 8 mg Dose Groups Who Achieved an American College of Rheumatology 20 (ACR20) Responder Index Response Baseline Through Week 12 . (12 weeks) 2012-11 | Percentage of Participants in the 4 mg and 8 mg Dose Groups Who Achieved an American College of Rheumatology 20 (ACR20) Responder Index Response Baseline Through Week 12 . (12 weeks): Part A: Combined 4 mg and 8 mg Baricitinib (LY3009104) 77 percentage of participants | Part A: Placebo 31 percentage of participants | not yet graded | link ↗ |
RA-BUILD NCT01721057 · Rheumatoid Arthritis Registry: NCT01721057 | 3 | Percentage of Participants Achieving American College of Rheumatology 20% Improvement (ACR20) (Week 12) 2014-09 | Percentage of Participants Achieving American College of Rheumatology 20% Improvement (ACR20) (Week 12): Placebo 39.5 percentage of participants | Baricitinib 2 mg 65.9 percentage of participants | Baricitinib 4 mg 61.7 percentage of participants | not yet graded | link ↗ |
RA-BEACON NCT01721044 · Rheumatoid Arthritis Registry: NCT01721044 | 3 | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response - Placebo Versus Baricitinib 4 mg (Week 12) 2014-06 | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response - Placebo Versus Baricitinib 4 mg (Week 12): Placebo 27.3 Percentage of Participants | Baricitinib 4 mg 55.4 Percentage of Participants | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (46)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (55)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (24)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 1 (1)
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2 (1)
What this study did
Competitive landscape
Other JAK drugs
tofacitinib, upadacitinib, filgotinib, ivarmacitinib, QLM3003 and 1 more. Compare all 7 JAK drugs
Other JAK1/2 drugs
Ruxolitinib (Jakafi), Ruxolitinib (Opzelura), pumecitinib. Compare all 4 JAK1/2 drugs
This mechanism is crowded: 9 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Alopecia Areata: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Baricitinib (Olumiant): this drug | Approved | Small molecule | JAK, JAK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| Ruxolitinib (Jakafi) | Approved(overall) | Small molecule | JAK1/2 | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Ivarmacitinib | Phase 3(overall) | Small molecule | JAK | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Jaktinib (Zepuping) | Phase 3 | Small molecule | JAK1/2/3 | Partial signal | NCT05051761: Primary endpoint, SALT score <=20 at week 24: both jaktinib doses superior to placebo (p<0.0001) (2024-06-13). | |
| Upadacitinib (Rinvoq) | Phase 3 | Small molecule | JAK, JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| Bempikibart | Phase 2 | Monoclonal antibody | IL-7 receptor alpha | Partial signal | NCT06018428: Part A primary, mean relative percent change in SALT score at week 24 vs placebo: the planned primary analysis was not performed after one site was excluded for protocol violations, so no primary-analysis result exists. Post-hoc per-protocol analysis (SALT 50-100): bempikibart (n=23) 16% mean reduction vs placebo (n=4) 2% reduction; Wilcoxon rank sum p=0.045. Part B is single-arm and has no comparison. | |
| Rezpegaldesleukin | Phase 2 | Protein / enzyme therapeutic | IL-2 mutein (Treg-selective) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
1 further pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(35 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Olumiant (baricitinib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (3)
December 2026 (3)
What to watch
What to watch
What to watch
2027 (9)
March 2027 (2)
June 2027 (1)
What to watch
July 2027 (1)
What to watch
August 2027 (1)
What to watch
October 2027 (1)
What to watch
November 2027 (1)
What to watch
December 2027 (2)
2028 (12)
January 2028 (2)
February 2028 (1)
What to watch
March 2028 (2)
June 2028 (1)
July 2028 (2)
August 2028 (1)
September 2028 (2)
November 2028 (1)
What to watch
2029 (5)
April 2029 (1)
What to watch
May 2029 (1)
What to watch
September 2029 (1)
What to watch
November 2029 (1)
What to watch
December 2029 (1)
What to watch
2030 (4)
February 2030 (1)
What to watch
May 2030 (1)
What to watch
July 2030 (1)
What to watch
December 2030 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent